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1LETTER TO THE EDITOR
ostexposure Prophylaxis Against Varicella Zoster
irus Infection Among Hematopoietic Stem Cell
ransplant Recipients
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dA comprehensive approach is essential to mini-
ize the morbidity caused by varicella zoster virus
VZV) among hematopoietic stem cell transplant
HSCT) recipients. However, prophylactic regimens
o prevent VZV infection among HSCT recipients are
ontroversial and vary widely [1]. Recently published
uidelines from a National Institutes of Health work-
ng group on criteria for clinical trials in chronic
raft-versus-host disease (GVHD) included the rec-
mmendation that “if VZV-seronegative patients with
hronic GVHD are exposed to varicella (primary or
ostvaccination illness), VZV Ig should be given
ithin 96 hours” [2]. We question this recommenda-
ion for 3 reasons: First, VZV Ig may be suboptimal;
econd, supplies of VZV Ig are limited; and third, the
ecommendation does not include an approach for
ZV-seropositive patients.
VZV Ig is only partially effective as postexposure
rophylaxis. In studies, 25%–45% of contacts treated
ith VZV Ig (including immunocompetent persons)
eveloped clinically apparent varicella [3,4]. In con-
rast, acyclovir has reasonable efﬁcacy as postexposure
rophylaxis. In a nonrandomized study, varicella de-
eloped in 16% of seronegative immunocompetent
hildren treated with acyclovir, compared with
00% of untreated controls [5]. Although no data
re available on acyclovir as postexposure prophy-
axis in HSCT recipients, extensive clinical experi-
nce indicates that acyclovir and valacyclovir are
ighly effective at preventing VZV reactivation in
hese patients [6-10].
After exposure to VZV disease (ie, varicella or
oster), patients who are not known to be VZV sero-
ositive should undergo VZV antibody testing.
ZV-seronegative HSCT recipients at Memorial
loan-Kettering Cancer Center (MSKCC) and
red Hutchinson Cancer Research Center (FHCRC)
re offered valacyclovir or acyclovir in addition to
ZV Ig. Based on institutional experience and extrap-
lation from the treatment of VZV disease, we use
alacyclovir 1 g po tid for patients weighing  40 kg
r 500 mg po tid for those weighing  40 kg on
ostexposure days 3–22. An alternative is acyclovir V
09600 mg/m2 po qid; valacyclovir is not recommended
or children under age 12 years. Because VZV Ig can
rolong the VZV incubation period [11], valacyclovir
or acyclovir) is administered on postexposure days
–28 in patients who are also receiving VZV Ig. VZV-
eronegative patients who are receiving acyclovir at
ower doses (eg, for HSV prophylaxis) receive the
igher dose on postexposure days 3–22 (or days 3–28
f VZV Ig was administered). Patients receiving stan-
ard induction or maintenance doses of gancyclovir,
oscarnet, or cidofovir do not require a change in
herapy after VZV exposure, because these agents are
ctive against VZV.
Postexposure prophylaxis against VZV infection
or patients who were VZV seropositive before HSCT
emains highly controversial. At least 57 immunocom-
romised patients with possible reinfection have been
eported [12]. Given that seropositive HSCT recipi-
nts may be at risk for reinfection, we offer all immu-
ocompromised HSCT recipients postexposure pro-
hylaxis. A particularly compelling point in favor of
ostexposure prophylaxis is the potential for false-
ositive VZV antibody results, especially in patients
ho have received immune globulin and other blood
roducts. Commercially available VZV antibody tests
lso vary markedly in sensitivity and speciﬁcity [13]
nd have not been adequately evaluated in immuno-
ompromised patients. However, seropositive HSCT
ecipients at MSKCC and FHCRC do not routinely
eceive VZV Ig postexposure prophylaxis. The low
isk of reinfection, the limited efﬁcacy of VZV Ig, and
ack of a VZV Ig dose–response relationship argue
gainst its routine use. Instead, seropositive patients
re routinely offered postexposure prophylaxis with
alacyclovir or acyclovir if  6 months after an autol-
gous HSCT or  12 months after an allogeneic
SCT, are receiving immunosuppressive therapy,
ave active GVHD, or are otherwise immunodeﬁcient
eg, CD4 count  200/L, recent opportunistic in-
ection). The single exception is seropositive patients
ho have previously experienced an episode of VZV
isease after HSCT, who appear to be at no risk for
ZV reinfection [11].
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Letter to the Editor 1097A ﬁnal approach not mentioned in the guidelines
s the postexposure management of VZV-susceptible
ousehold members or close contacts of HSCT recip-
ents. Considering the inordinately high risk of trans-
ission from household and other close contacts, we
ecommend an aggressive treatment strategy to avoid
ZV disease in this group. If a VZV-susceptible
ousehold member or close contact of an HSCT re-
ipient is exposed to VZV, then the contact should
ndergo VZV vaccination. A study of immunocompe-
ent children vaccinated within 3 days of exposure
ound a protective efﬁcacy of VZV vaccine as postex-
osure prophylaxis of approximately 90% [14]. If in-
ligible for vaccine, the exposed contact should receive
alacylcovir or acyclovir. If VZV Ig becomes readily
vailable in the future at a reasonable cost, it may be
easonable to administer VZV Ig, in addition to vala-
yclovir or acyclovir, to the exposed contact, because
his combination would likely offer greater protection
han either agent alone. Contact between the exposed
erson and the HSCT recipient should be minimized
o the greatest extent possible on postexposure days
0–21 (or days 10–28 if VZV Ig was administered)
fter exposure. If the contact is vaccinated, then vac-
ine-strain varicella could potentially be transmitted
o the HSCT recipient. This risk appears to be small,
nd VZV disease transmitted from vaccine recipients
s generally mild [15].
This comprehensive approach to preventing post-
xposure VZV disease is used routinely at our institu-
ions. Although randomized trials are lacking, the ex-
ellent safety record of these agents and the high risk
or morbidity and mortality from VZV disease among
SCT recipients support the use of an aggressive
trategy for postexposure prophylaxis.
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